Investment
Features
FeesSafety
Academy
More
Pluang+

Fidelity National Financial to report Q3 2026 earnings on Nov 5 with webcast and call on Nov 6

Company Fundamentals
05 Oct 2026
PRNewsWire
View Source
Neutral
Fidelity National Financial to report Q3 2026 earnings on Nov 5 with webcast and call on Nov 6

Fidelity National Financial, a leading title insurance and insurance solutions provider, will release its third quarter 2026 earnings after market close on November 5, 2026. The company will hold a webcast and conference call at 11:00 a.m. Eastern Time on November 6 to discuss the results. Investors can access the event via Fidelity's Investor Relations website or by phone. This earnings report will provide insights into the company's financial health and performance in the real estate and insurance sectors.

Fidelity National Financial's upcoming third quarter 2026 earnings release and conference call provide context for readers following this company. For readers following the Financials sector, here is Pluang's market snapshot as of Oct 06, 2026 02:42 WIB: out of 85 priced Financials-sector US stocks tradable on Pluang, 60 rose and 24 fell today. Notable movers include COIN at USD 188.88 with a 1-day change of +3.21%, MSCI at USD 552.75 with +3.13%, and PYPL at USD 54.30 with +2.84%.

More News

Applied Digital eyes $1B net income by 2027 amid AI data center expansion, Q1 loss expected.

Applied Digital eyes $1B net income by 2027 amid AI data center expansion, Q1 loss expected.

Applied Digital is set to report a fiscal Q1 loss of $0.30 per share on $116.3 million revenue, reflecting ongoing investments in AI and high-performance data centers. The company has expanded its Polaris Forge 1 campus to 250 MW operational capacity...

Company Fundamentals
Bullish
1 hour ago
Needham raises Vaxcyte price target after strong Phase 3 trial of VAX-31 vaccine

Needham raises Vaxcyte price target after strong Phase 3 trial of VAX-31 vaccine

Investment firm Needham increased its price target for Vaxcyte to $122 from $110 following positive Phase 3 trial results for Vaxcyte's VAX-31 pneumococcal vaccine. The vaccine met all primary endpoints in the OPUS-1 trial, showing noninferiority to ...

Analyst Insights
Bullish
2 hours ago
GMAB's Rina-S shows 45.9% response in ovarian cancer trial, advancing to Phase 3 studies.

GMAB's Rina-S shows 45.9% response in ovarian cancer trial, advancing to Phase 3 studies.

GMAB's investigational drug Rina-S demonstrated a 45.9% confirmed response rate in a Phase 1/2 trial for platinum-resistant ovarian cancer, with a median response duration of 12.1 months and median progression-free survival of 9.5 months. Despite ser...

Market News
Bullish
3 hours ago
Aptos Labs proposes encrypted mempool to protect pending trades, adding 27ms latency if approved by governance.

Aptos Labs proposes encrypted mempool to protect pending trades, adding 27ms latency if approved by governance.

Aptos Labs has proposed an encrypted mempool feature that hides pending trade instructions until transaction ordering is complete, aiming to protect orders from frontrunning and censorship. Tests showed the feature adds 27 milliseconds of latency, ab...

Protocol Fundamentals
Bullish
4 hours ago
Pacific Booker plans $10M private placement to fund Morrison project development.

Pacific Booker plans $10M private placement to fund Morrison project development.

Pacific Booker Minerals Inc. announced a non-brokered private placement to raise up to $10 million by selling 4,273,505 units at $2.34 each. Each unit includes one common share and one warrant to buy another share at $2.75 within 36 months. The funds...

Company Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App